Steqeyma

Active Ingredient(s): Ustekinumab-stba
FDA Approved: * December 17, 2024
Pharm Company: * CELLTRION, INC.
Category: Immunosuppressive

Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis,[5] targeting both IL-12 and IL-23.[6] Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the US, and in the EU to patients who have not responded to m... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Steqeyma 45 mg/.5ml Subcutaneous Injection, Solution
NDC: 72606-027
Labeler:
Celltrion Inc.
Steqeyma 90 mg/ml Subcutaneous Injection, Solution
NDC: 72606-028
Labeler:
Celltrion Inc.
Steqeyma 130 mg/26ml Intravenous Injection, Solution
NDC: 72606-029
Labeler:
Celltrion Inc.

Related Brands

Drugs with the same active ingredients